Research Analysts Issue Forecasts for RIGL Q3 Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Investment analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Rigel Pharmaceuticals in a research note issued to investors on Wednesday, March 5th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings of $0.34 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $57.00 target price on the stock. The consensus estimate for Rigel Pharmaceuticals' current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals' Q4 2025 earnings at $0.48 EPS.

Other analysts have also issued research reports about the company. Citigroup increased their price objective on Rigel Pharmaceuticals from $49.00 to $55.00 and gave the company a "buy" rating in a research note on Thursday. Piper Sandler lifted their price target on shares of Rigel Pharmaceuticals from $15.00 to $23.00 and gave the stock a "neutral" rating in a report on Thursday, November 14th. B. Riley boosted their price objective on shares of Rigel Pharmaceuticals from $20.00 to $24.00 and gave the company a "neutral" rating in a research report on Wednesday, March 5th. StockNews.com lowered shares of Rigel Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Finally, Cantor Fitzgerald boosted their price target on Rigel Pharmaceuticals from $15.00 to $25.00 and gave the company a "neutral" rating in a report on Tuesday, December 10th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $36.80.

Remove Ads

Rigel Pharmaceuticals Price Performance

Rigel Pharmaceuticals stock traded down $0.99 during mid-day trading on Thursday, hitting $19.53. 343,303 shares of the company were exchanged, compared to its average volume of 246,467. Rigel Pharmaceuticals has a 12-month low of $7.48 and a 12-month high of $29.82. The company has a market capitalization of $348.86 million, a P/E ratio of 139.51 and a beta of 1.35. The business's 50 day simple moving average is $20.28 and its two-hundred day simple moving average is $18.62.

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) last announced its quarterly earnings results on Tuesday, March 4th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.50. Rigel Pharmaceuticals had a net margin of 2.46% and a negative return on equity of 14.80%. The company had revenue of $57.60 million for the quarter, compared to the consensus estimate of $57.59 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Soleus Capital Management L.P. lifted its holdings in shares of Rigel Pharmaceuticals by 21.0% during the 4th quarter. Soleus Capital Management L.P. now owns 1,130,679 shares of the biotechnology company's stock valued at $19,018,000 after acquiring an additional 195,891 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Rigel Pharmaceuticals by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 1,012,931 shares of the biotechnology company's stock worth $17,038,000 after buying an additional 27,640 shares during the period. Geode Capital Management LLC grew its stake in shares of Rigel Pharmaceuticals by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 402,051 shares of the biotechnology company's stock valued at $6,764,000 after buying an additional 2,388 shares in the last quarter. State Street Corp raised its holdings in shares of Rigel Pharmaceuticals by 0.7% during the 3rd quarter. State Street Corp now owns 367,795 shares of the biotechnology company's stock valued at $5,951,000 after buying an additional 2,552 shares during the period. Finally, Stonepine Capital Management LLC lifted its position in Rigel Pharmaceuticals by 1.3% during the 3rd quarter. Stonepine Capital Management LLC now owns 309,100 shares of the biotechnology company's stock worth $5,001,000 after acquiring an additional 4,100 shares in the last quarter. 66.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Dean L. Schorno sold 2,036 shares of Rigel Pharmaceuticals stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $20.92, for a total value of $42,593.12. Following the transaction, the chief financial officer now owns 58,969 shares in the company, valued at approximately $1,233,631.48. This trade represents a 3.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David A. Santos sold 2,125 shares of the company's stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $20.92, for a total value of $44,455.00. Following the sale, the executive vice president now owns 53,500 shares of the company's stock, valued at $1,119,220. This represents a 3.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 9,113 shares of company stock valued at $190,644 in the last ninety days. Company insiders own 9.04% of the company's stock.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.